http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Article/list/42855 Written by Physicians, For Physicians Ophthalmology Times is an award-winning physician-driven publication that disseminates news and information of a clinical, socio-economic, and political nature in a timely and accurate manner for members of the ophthalmic community. 2009-11-21T07:32:44Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Pieris-Allergan-collaborate-to-develop-treatments/ArticleStandard/Article/detail/631230?contextCategoryId=42855&ref=25 Pieris AG and Allergan will collaborate in the development of agents to treat serious ocular disorders, Pieris has announced. 2009-10-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412009/631230null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Bausch-amp-Lomb-subsidiaries-CROMA-to-co-promote-b/ArticleStandard/Article/detail/631233?contextCategoryId=42855&ref=25 Several subsidiaries of Bausch & Lomb have been granted rights from CROMA Pharma GmbH to co-promote and sell bromfenac ophthalmic solution in Europe when it becomes available to that market, announced Bausch & Lomb. 2009-10-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412009/631233null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/FDA-clears-Topcon-digital-fundus-camera/ArticleStandard/Article/detail/631229?contextCategoryId=42855&ref=25 The FDA has granted 510(k) clearance to a new digital fundus camera (TRC-NW7SF Mark II, Topcon Medical Systems), according to its manufacturer. 2009-10-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412009/631229null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Ophthalmology/I-Therapeutix-changes-name-to-Ocular-Therapeutix/ArticleStandard/Article/detail/631238?contextCategoryId=42855&ref=25 I-Therapeutix has changed its name to Ocular Therapeutix. 2009-10-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412009/631238null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/AMO-launches-online-ordering-service/ArticleStandard/Article/detail/631232?contextCategoryId=42855&ref=25 Abbott Medical Optics (AMO) has launched a new online ordering service (AMOeasy, www.amoeasy.com) whereby customers can order the company?s implants and other cataract-related products as well as track orders at any time of day. 2009-10-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412009/631232null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Dr-Travis-Meredith-is-new-AUPO-president/ArticleStandard/Article/detail/626560?contextCategoryId=42855&ref=25 Travis Meredith, MD, has been elected as the new president of the Association of University Professors of Ophthalmology (AUPO), which is composed of department chairmen, residency directors, and research directors of ophthalmology departments in the United States and Canada, according to a prepared statement. 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626560null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Alcon-to-acquire-ESBATech/ArticleStandard/Article/detail/626549?contextCategoryId=42855&ref=25 Alcon has announced in a prepared statement that it has entered into a definitive agreement to acquire ESBATech AG, a Swiss biotechnology company. 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626549null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Bausch-amp-Lomb-to-consolidate-its-contact-lens-ma/ArticleStandard/Article/detail/626559?contextCategoryId=42855&ref=25 Bausch & Lomb intends to consolidate its worldwide contact lens manufacturing and proposes to begin moving most of its global contact lens production to its existing sites in Waterford, Ireland, and Rochester, NY, according to a prepared statement. ?? 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626559null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Abbott-expected-to-acquire-Visiogen/ArticleStandard/Article/detail/626555?contextCategoryId=42855&ref=25 Abbott has announced a definitive agreement to acquire Visiogen Inc. for $400 million in cash, providing the company with a next-generation accommodating IOL technology (Synchrony), according to a prepared statement. 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626555null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Jeffrey-P-Gilbard-MD-Dry-eye-pioneer-product-devel/ArticleStandard/Article/detail/627837?contextCategoryId=42855&ref=25 Fellow ophthalmologists and business partners are mourning the loss of Jeffrey P. Gilbard, MD, 55, whose career was filled with innovative ideas and solutions for treating dry eye disease. 2009-09-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627837null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Feature+Articles/Abbott-to-buy-Visiogen-for-400-million/ArticleStandard/Article/detail/624117?contextCategoryId=42855&ref=25 Abbott announced a definitive agreement to acquire Visiogen Inc. for $400 million, providing the company with a next-generation accommodating IOL technology to address presbyopia for patients with cataracts. 2009-09-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/362009/624117null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Pfizer-Private-Access-aim-to-accelerate-clinical-r/ArticleStandard/Article/detail/623230?contextCategoryId=42855&ref=25 Pfizer has entered into a collaboration with Private Access to create a new online community aimed at increasing clinical trial awareness and participation. It will be rolled out in phases starting late this year. 2009-09-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/362009/623230null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/CSI-Miami-episode-to-feature-Reichert-instrument/ArticleStandard/Article/detail/623204?contextCategoryId=42855&ref=25 The CBS crime drama 'CSI: Miami' will feature a proprietary automated lensometer (AL200, Reichert) in an episode airing Oct. 12, according to its manufacturer. 2009-09-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/362009/623204null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Art-exhibit-focuses-on-macular-degeneration/ArticleStandard/Article/detail/623206?contextCategoryId=42855&ref=25 To mark the global observance of AMD [age-related macular degeneration] Week, Lighthouse International and AMD Alliance International (AMDAI) will host an exhibit of the works of London-based portrait artist Adam Hahn, whose paintings illustrate how patients with AMD see the world. 2009-09-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/362009/623206null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/STAAR-Surgical-reports-progress-on-application-to-/ArticleStandard/Article/detail/623225?contextCategoryId=42855&ref=25 STAAR Surgical Co. President and Chief Executive Officer Barry G. Caldwell said he is “encouraged and pleased” with feedback the company has received from the Japanese government regarding the possibility of marketing its implantable contact lens ([ICL] Visian Implantable Collamer Lens) products there. 2009-09-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/362009/623225null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Hideo-Ozawa-Nidek-founder-merged-optics-electronic/ArticleStandard/Article/detail/627659?contextCategoryId=42855&ref=25 Hideo Ozawa, the founder and chairman of Nidek Co. Ltd., is being remembered as a visionary who combined optics and electronics to advance vision technology around the world. Ozawa, 79, died June 16. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627659null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/September-is-named-by-PBA-as-Home-Eye-Safety-Aware/ArticleStandard/Article/detail/623622?contextCategoryId=42855&ref=25 One in five at-home eye injuries are due to home repair or power tools according to results from the ?Sixth Annual Eye Injury Snapshot? by the American Academy of Ophthalmology and the American Society of Ocular Trauma. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/362009/623622null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Bausch-amp-Lomb-opens-new-pharma-headquarters/ArticleStandard/Article/detail/627655?contextCategoryId=42855&ref=25 Bausch & Lomb has opened a new 300,000-square-foot global pharmaceutical headquarters building in Madison, NJ. The company maintains its worldwide headquarters in Rochester, NY, and has research and development functions in locations around the world. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627655null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Santen-expands-its-business-development-efforts/ArticleStandard/Article/detail/619791?contextCategoryId=42855&ref=25 Santen Inc. has announced the establishment of a satellite office in Irvine, CA, which will be the base of operations for its business development staff. 2009-08-19T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/342009/619791null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Dr-Jeffrey-Gilbard-pioneer-for-dry-eye-disease-tre/ArticleStandard/Article/detail/619782?contextCategoryId=42855&ref=25 Jeffrey Gilbard, MD, founder and chief executive officer of Advanced Vision Research, died Aug. 12 at Massachusetts General Hospital, Boston, following complications related to a bicycle accident. He was 55. 2009-08-19T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/342009/619782null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/NicOx-and-Pfizer-sign-agreement-for-PF-03187207/ArticleStandard/Article/detail/619794?contextCategoryId=42855&ref=25 NicOx has signed an agreement with Pfizer to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open-angle glaucoma and ocular hypertension, according to a prepared statement. 2009-08-19T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/342009/619794null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Bascom-Palmer-Albert-Einstein-name-chairmen/ArticleStandard/Article/detail/619329?contextCategoryId=42855&ref=25 Two prominent cornea specialists have been appointed chairmen of ophthalmology departments in Miami and New York City. 2009-08-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/342009/619329null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/NicOx-to-reacquire-from-Pfizer-rights-to-experimen/ArticleStandard/Article/detail/617973?contextCategoryId=42855&ref=25 NicOx announced an agreement to reacquire the development and commercialization rights to an experimental glaucoma medicine from partner company Pfizer. 2009-08-11T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/332009/617973null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Bausch-amp-Lomb-opens-new-pharmaceutical-headquart/ArticleStandard/Article/detail/615725?contextCategoryId=42855&ref=25 Bausch & Lomb has opened a new 30,000-square-foot global pharmaceutical headquarters building in Madison, NJ. 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/615725null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+News/Nov-1-is-new-enforcement-date-for-Red-Flags-Rule/ArticleStandard/Article/detail/615696?contextCategoryId=42855&ref=25 The Federal Trade Commission has announced another delay—Nov. 1—in the enforcement of the "Red Flags Rule" to give creditors and financial institutions more time to develop and implement written identity theft prevention programs. 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/615696null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Vistakon-executive-dies-in-plane-crash/ArticleStandard/Article/detail/615737?contextCategoryId=42855&ref=25 Pat Cummings, OD, Vistakon America's region vice president, professional development group, was killed in a plane crash July 11 in Florida. 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/615737null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Mass-Eye-and-Ear-receives-126-million-after-vertep/ArticleStandard/Article/detail/615684?contextCategoryId=42855&ref=25 The Massachusetts Eye and Ear Infirmary in Boston has received $126 million from the recent resolution of a nearly decade-long lawsuit concerning the hospital's role in the development of verteporfin for injection (Visudyne). 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/615684null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Alcon-AstraZeneca-to-collaborate-on-eye-drug-devel/ArticleStandard/Article/detail/615728?contextCategoryId=42855&ref=25 Alcon Inc. has entered into a 5-year collaborative research agreement with AstraZeneca for the exclusive ophthalmic discovery and potential development rights to AstraZeneca's compound library. 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/615728null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/House-Senate-pass-legislation-for-NEIs-40th-annive/ArticleStandard/Article/detail/610829?contextCategoryId=42855&ref=25 The U.S. House of Representatives has passed H. Res. 366, and the Senate has passed S. Res. 209, both of which recognize the 40th anniversary of the National Eye Institute (NEI) and support designation of 2010 to 2020 as the "Decade of Vision," according to prepared statements. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610829null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/TearLab-appoints-Vamvakas-as-interim-CEO/ArticleStandard/Article/detail/610828?contextCategoryId=42855&ref=25 TearLab Corp. announced that Eric Donsky, chief executive officer (CEO), has left the company to pursue other opportunities. The company's board of directors has appointed its chairman, Elias Vamvakas, to serve as interim CEO until a permanent replacement can be found. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610828null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Dr-Alfonso-named-chairman-at-Bascom-Palmer/ArticleStandard/Article/detail/610826?contextCategoryId=42855&ref=25 Eduardo C. Alfonso, MD, has been named chairman of the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, according to a prepared statement. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610826null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Alcon-discontinues-development-of-anecortave-aceta/ArticleStandard/Article/detail/610827?contextCategoryId=42855&ref=25 Alcon Inc. announced it has discontinued development of anecortave acetate for the reduction of IOP associated with glaucoma. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610827null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Cornea/Bascom-Palmer-names-Eduardo-C-Alfonso-MD-its-new-c/ArticleStandard/Article/detail/608859?contextCategoryId=42855&ref=25 Eduardo C. Alfonso, MD, is the new chairman of the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine. Dr. Alfonso is the fifth chairman to be named in the institute's 47-year history. 2009-07-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/282009/608859null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Nidek-founder-and-chairman-remembered/ArticleStandard/Article/detail/606854?contextCategoryId=42855&ref=25 Hideo Ozawa, founder and chairman of the board of Nidek Co. Ltd., died June 16 at a hospital in Gamagori, Japan. He was 79. 2009-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/606854null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Dr-Chuck-named-chairman-at-Einstein-Montefiore/ArticleStandard/Article/detail/606852?contextCategoryId=42855&ref=25 Roy S. Chuck, MD, PhD, has been appointed chairman of ophthalmology and visual sciences at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center. The appointment is effective July 1. 2009-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/606852null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/A-new-progressive-addition-lens-enters-the-market/ArticleStandard/Article/detail/609492?contextCategoryId=42855&ref=25 A next-generation progressive addition lens (Definity, Essilor of America Inc.) features proprietary technology (Dual Add 2.0 ) and design in clear (Trivex) material and gray and brown (Transitions VI). 2009-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/282009/609492null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Harvard-affiliates-collaborate-on-pediatric-ophtha/ArticleStandard/Article/detail/606853?contextCategoryId=42855&ref=25 Two affiliates of Harvard Medical School's Department of Ophthalmology will begin a formal relationship in patient care Aug. 1, creating what the institutions describe as one of the most comprehensive pediatric ophthalmology networks in the country. 2009-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/606853null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Gibson-appointed-director-of-development-for-Glauc/ArticleStandard/Article/detail/605751?contextCategoryId=42855&ref=25 The Glaucoma Research Foundation announced the addition of Candler Gibson as the new director of development. 2009-06-22T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/605751null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/PBO-warns-of-the-potential-danger-of-fireworks/ArticleStandard/Article/detail/604758?contextCategoryId=42855&ref=25 Prevent Blindness Ohio (PBO) urges the public to refrain from purchasing or using backyard fireworks for Fourth of July celebrations. 2009-06-18T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252009/604758null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Joint-Commission-clarifies-its-position-on-sterili/ArticleStandard/Article/detail/604152?contextCategoryId=42855&ref=25 A new position statement has been released by the Joint Commission to clarify the interpretation of standards regarding steam sterilization. 2009-06-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252009/604152null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Abbott-Medical-Optics-halts-future-production-of-3/ArticleStandard/Article/detail/602848?contextCategoryId=42855&ref=25 Abbott Medical Optics said it has decided to halt future production of its newest ophthalmic viscosurgical device, 3% sodium hyaluronate (Healon D), citing concerns about the company's ability to ensure a continuous supply to the market. 2009-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/602848null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Latanoprost-solution-for-glaucoma-is-included-in-p/ArticleStandard/Article/detail/602842?contextCategoryId=42855&ref=25 Newly unemployed Americans and their families who have lost their health insurance coverage and who are taking Pfizer branded medicines, including latanoprost ophthalmic solution (Xalatan), may be eligible for free medicine under a new patient assistance program launched by the manufacturer. 2009-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/602842null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/PBO-PBA-award-grants-in-celebration-of-Vision-Rese/ArticleStandard/Article/detail/603738?contextCategoryId=42855&ref=25 Prevent Blindness Ohio (PBO), along with Prevent Blindness America (PBA), has named June as Vision Research Awareness month. 2009-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252009/603738null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Bascom-Palmer-Wilmer-Eye-top-Best-Hospitals-list-f/ArticleStandard/Article/detail/603369?contextCategoryId=42855&ref=25 Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, took the top spot in a U.S. News and World Report "Best Hospitals" ranking, and the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, took the second spot. 2009-06-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/603369null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/STAAR-Surgical-receives-CE-mark-for-preloaded-lens/ArticleStandard/Article/detail/603385?contextCategoryId=42855&ref=25 STAAR Surgical announced that it has received CE mark approval for its proprietary foldable IOL injector system (KS-X preloaded hydrophobic acrylic injector), which is used in minimally invasive cataract surgery procedures. 2009-06-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/603385null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/OCT-system-with-RNFL-and-macular-databases-approve/ArticleStandard/Article/detail/602910?contextCategoryId=42855&ref=25 A new optical coherence tomography (OCT) software application (Cirrus [high-definition] HD-OCT, Carl Zeiss Meditec) has been cleared by the FDA for commercial distribution. 2009-06-11T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/602910null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/EyeCare-of-America-program-provides-free-eye-care-/ArticleStandard/Article/detail/602148?contextCategoryId=42855&ref=25 EyeCare of America, a program of the Foundation of the American Academy of Ophthalmology, will be offering "Don't Lose Sight of Your Independence," a national health campaign intended to remind the senior community of the value of eyesight. 2009-06-08T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/602148null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/FDA-approves-besifloxacin-for-bacterial-conjunctiv/ArticleStandard/Article/detail/601021?contextCategoryId=42855&ref=25 Silver Spring, MD—The FDA has approved besifloxacin ophthalmic suspension 0.6% (Besivance, Bausch & Lomb) for the treatment of bacterial (non-viral) conjunctivitis, the agency announced. 2009-06-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/232009/601021null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Alcon-breaks-ground-on-Singapore-plant/ArticleStandard/Article/detail/600381?contextCategoryId=42855&ref=25 Alcon Inc. has begun construction of its first pharmaceutical manufacturing plant in the Asian region. 2009-06-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/600381null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Pfizer-to-provide-free-drugs-to-newly-unemployed/ArticleStandard/Article/detail/600380?contextCategoryId=42855&ref=25 Pfizer Inc. has launched a new program, called MAINTAIN (Medicines Assistance for Those who Are in Need), to provide access to the company's drugs at no charge to eligible unemployed Americans and their families who have lost their health insurance. 2009-06-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/600380null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Bausch-amp-Lomb-announces-new-surgical-instruments/ArticleStandard/Article/detail/600390?contextCategoryId=42855&ref=25 Bausch & Lomb has introduced two new Web sites focused on its surgical instruments business. 2009-06-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/600390null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Date-set-for-FDA-review-of-bepotastine/ArticleStandard/Article/detail/601024?contextCategoryId=42855&ref=25 Irvine, CA—June 26 is the day the FDA Dermatologic and Ophthalmic Drugs Advisory Committee will review ISTA Pharmaceuticals' new drug application (NDA) for bepotastine ophthalmic solution (Bepreve), the company has announced. The company is seeking approval for the non-sedating, highly selective antagonist of the histamine (H1) receptor as an eye-drop treatment for ocular itching associated with allergic conjunctivitis. 2009-06-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/232009/601024null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/TearLab-Corp-gets-510k-clearance-for-osmolarity-sy/ArticleStandard/Article/detail/600382?contextCategoryId=42855&ref=25 OccuLogix Inc., conducting business as TearLab Corp., has received 510(k) clearance from the FDA for the company's system (TearLab Osmolarity System) to measure the osmolarity of human tears to aid in the diagnosis of dry eye disease in conjunction with other methods of clinical evaluation. 2009-06-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/600382null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/WesternU-KGI-collaborate-on-dual-degree-program/ArticleStandard/Article/detail/600386?contextCategoryId=42855&ref=25 Keck Graduate Institute of Applied Life Sciences (KGI), Claremont, CA, and the Western University of Health Sciences College of Pharmacy (WesternU), Pomona, CA, are developing a dual-degree program designed to equip students with skills that are highly regarded by the pharmaceutical industry and specialty health-care organizations. 2009-06-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/600386null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Dispensing+News/Eye-related-allergies-may-prevent-use-of-contact-l/ArticleStandard/Article/detail/600623?contextCategoryId=42855&ref=25 Eye-related allergy symptoms may prevent many people from wearing contact lenses, according to 800 respondents of an online survey led by the Asthma and Allergy Foundation of America. 2009-05-29T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/600623null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/Paradigm-Medical-seeks-upgraded-CPT-code-for-its-t/ArticleStandard/Article/detail/600354?contextCategoryId=42855&ref=25 Paradigm Medical Industries Inc. has announced its plans to upgrade its Current Procedural Terminology (CPT) code (0189T) for its tonometer (Ocular Blood Flow Analyzer) from the American Medical Association from an investigational level (Class III). 2009-05-28T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/600354null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Bausch-and-Lomb-names-new-vision-care-presidents/ArticleStandard/Article/detail/598759?contextCategoryId=42855&ref=25 Bausch & Lomb has named Peter Valenti III as corporate vice president and global president of vision care, effective July 1. 2009-05-19T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/212009/598759null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Dr-Soriot-leads-Genentech-as-Roche-makes-moves/ArticleStandard/Article/detail/599623?contextCategoryId=42855&ref=25 Pascal Soriot, DVM, MBA, has been named chief executive officer (CEO) of Genentech, leading all of the company's pharmaceutical activities in the United States and reporting directly to Severin Schwan, Roche Group CEO. 2009-05-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/599623null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Essilor-renews-partnership-with-Special-Olympics-L/ArticleStandard/Article/detail/597970?contextCategoryId=42855&ref=25 Essilor of America Inc. has announced a 3-year extension of Essilor International?s partnership with the Special Olympics Lions Club International Opening Eyes program. 2009-05-13T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/202009/597970null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Pfizer-University-College-London-form-AMD-collabor/ArticleStandard/Article/detail/596748?contextCategoryId=42855&ref=25 Pfizer Regenerative Medicine has entered into a collaboration and license agreement with University College London with a goal of developing stem cell-based therapies primarily for wet and dry age-related macular degeneration (AMD) but for other retinal diseases as well. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596748null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/STAAR-Surgical-releases-aspheric-single-piece-IOL/ArticleStandard/Article/detail/596736?contextCategoryId=42855&ref=25 STAAR Surgical Co. has announced the release of a new IOL (Afinity Collamer Aspheric Single Piece New Technology IOL. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596736null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Dr-Soriot-leads-Genentech-as-Roche-announces-organ/ArticleStandard/Article/detail/596745?contextCategoryId=42855&ref=25 Pascal Soriot, DVM, MBA, has been named chief executive officer (CEO) of Genentech, leading all of the company?s pharmaceutical activities in the United States and reporting directly to Severin Schwan, Roche Group CEO. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596745null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Sirion-Therapeutics-receives-fast-track-designatio/ArticleStandard/Article/detail/596747?contextCategoryId=42855&ref=25 The FDA has granted fast-track designation to Sirion Therapeutics? fenretinide for the treatment of geographic atrophy associated with age-related macular degeneration, according to the company. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596747null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Dr-Camras-noted-glaucoma-researcher-dies/ArticleStandard/Article/detail/596743?contextCategoryId=42855&ref=25 Carl Camras, MD, whose research helped usher in the use of prostaglandin analogues for the treatment of glaucoma, died April 14. He was 55. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596743null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Merck-Santen-sign-agreement-for-prostaglandin-anal/ArticleStandard/Article/detail/596740?contextCategoryId=42855&ref=25 Merck & Co. Inc. and Santen Pharmaceutical Co. Ltd. have announced a worldwide licensing agreement for tafluprost, a prostaglandin analogue under investigation in the United States. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596740null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Abbott-acquisition-of-Adavanced-Medical-Optics-a-w/ArticleStandard/Article/detail/599654?contextCategoryId=42855&ref=25 Jim Mazzo, who led Advanced Medical Optics from fledgling spin-off to a major player in the ophthalmology industry, tells Ophthalmology Times that the company will continue to grow and develop new products as part of Illinois-based Abbott Inc. 2009-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/599654null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Eyelash-drug-launched-at-national-event/ArticleStandard/Article/detail/599650?contextCategoryId=42855&ref=25 A reformulation of a prostaglandin analogue used to treat glaucoma was launched April 2 as a treatment for hypotrichosis of the eyelashes. 2009-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/599650null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/American-Society-of-Cataract-and-Refractive-Surger/ArticleStandard/Article/detail/599639?contextCategoryId=42855&ref=25 At the opening session of the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, Bradford J. Shingleton, MD, addressed the activities performed and accomplishments made during his 1-year term as the society's president. Alan S. Crandall, MD, incoming ASCRS president, encouraged participation from all ophthalmologists and pledged his commitment in handling the challenges the upcoming year may hold. 2009-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/599639null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/ARVO-will-continue-no-reported-swine-flu-in-Florid/ArticleStandard/Article/detail/595964?contextCategoryId=42855&ref=25 The Association for Research in Vision and Ophthalmology (ARVO) annual meeting attendees along with ARVO staff have started to arrive in Fort Lauderdale. 2009-04-30T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/182009/595964null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Paradigm-redefines-its-role-within-glaucoma-ophtha/ArticleStandard/Article/detail/595355?contextCategoryId=42855&ref=25 Paradigm Medical Industries said it has plans to reorganize and reposition itself within the ophthalmic market. Plans include engineering improvements to many of its products and an assessment of its operations efforts. 2009-04-28T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/182009/595355null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Roche-executive-becomes-CEO-of-Genentech-former-CE/ArticleStandard/Article/detail/594799?contextCategoryId=42855&ref=25 Roche plans to keep the chairman and chief executive of recently acquired Genentech on board as chairman of the unit and named a Roche executive as its new chief executive officer (CEO), according to the company. 2009-04-23T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/172009/594799null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/Ophthalmologists-cite-benefits-of-preservative-fre/ArticleStandard/Article/detail/593318?contextCategoryId=42855&ref=25 In a recent survey of U.S. ophthalmologists, 97% believe preservative-free glaucoma medications can enhance the ocular comfort of patients with glaucoma, whereas 86% believe that preservative-free glaucoma medications can enhance patient quality of life. 2009-04-14T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/162009/593318null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Dispensing+News/Free-bilingual-eye-exam-guide-available-to-eye-car/ArticleStandard/Article/detail/593321?contextCategoryId=42855&ref=25 'What to Expect: Bilingual Eye Exam Guide' (Transitions) has been developed to help facilitate dialogue during an eye examination between English-speaking eye-care professionals and Hispanic patients. 2009-04-14T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/162009/593321null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Cataract/ASCRS-New-intraoperative-wavefront-aberrometer-deb/ArticleStandard/Article/detail/591938?contextCategoryId=42855&ref=25 San Francisco—Refractive-cataract surgeons now have a tool to guide the outcomes of their cataract procedures (ORange Intraoperative Wavefront Aberrometer, WaveTec Vision). 2009-04-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152009/591938null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/ASCRS-Real-time-messaging-connects-eye-care-practi/ArticleStandard/Article/detail/591939?contextCategoryId=42855&ref=25 San Francisco—A practice-to-patient communication service from Smile Reminder helps vision-care providers communicate directly with patients by automatically sending text or e-mail messages. 2009-04-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152009/591939null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/ASCRS-Surgical-instrument-continuing-education-pro/ArticleStandard/Article/detail/591747?contextCategoryId=42855&ref=25 San Francisco—Bausch & Lomb Storz Ophthalmic Instruments recently launched two new continuing education programs available at www.StorzOphthalmicCE.com. Participants will receive contact hours approved by the Certification Board for Sterile Processing and Distribution Inc., the International Association for Healthcare Central Service Material Management, and the Texas Nurses Association. 2009-04-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152009/591747null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/ASCRS-Next-generation-laser-system-features-shorte/ArticleStandard/Article/detail/591746?contextCategoryId=42855&ref=25 San Francisco—Through an increase in the pulse repetition rate, a new femtosecond laser system (VisuMax, Carl Zeiss Meditec) enhances the precision of therapy, shortens treatment times, and further improves patient comfort, said the manufacturer in a prepared statement. 2009-04-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152009/591746null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Cataract/ASCRS-Training-program-helps-surgeons-boost-premiu/ArticleStandard/Article/detail/591707?contextCategoryId=42855&ref=25 San Francisco—The first session of a unique training program, Premium Lens Boot Camp, to help refractive and cataract surgeons grow their accommodating/multifocal lens business will be held June 5 at the O'Hare Marriott, Chicago. 2009-04-04T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/591707null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/ASCRS-Three-experts-weigh-in-with-advice-for-the-p/ArticleStandard/Article/detail/591531?contextCategoryId=42855&ref=25 San Francisco—What advice would you give to President Obama to help navigate health-care reform? Three people well acquainted with the challenges that the president will face answered that question here at Glaucoma Day. 2009-04-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/591531null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma+News/ASCRS-Ways-to-reduce-the-pressure-of-the-recession/ArticleStandard/Article/detail/591532?contextCategoryId=42855&ref=25 San Francisco—If you had a very ill patient, you would examine his or her vital signs frequently. The same holds true when the "patient" is the U.S. economy, said John B. Pinto, of the ophthalmic practice management consulting firm J. Pinto & Associates. 2009-04-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/591532null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/American-Glaucoma-Society-sees-record-attendance-g/ArticleStandard/Article/detail/593668?contextCategoryId=42855&ref=25 The 2009 annual meeting of the American Glaucoma Society (AGS), March 5 to 8, experienced record attendance, according to officers of the organization, with 619 members and an additional 75 attendees participating. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/162009/593668null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Favorable-safety-efficacy-seen-in-12-month-interim/ArticleStandard/Article/detail/590896?contextCategoryId=42855&ref=25 Alimera Sciences Inc., has made available the interim, 12-month safety and efficacy data from the first human pharmacokinetic study of fluocinolone acetonide intravitreal insert (Iluvien), which is currently under development for the treatment of diabetic macular edema, the company said in a prepared statement. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/590896null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Roche-and-Genentech-prepare-to-merge-blend-corpora/ArticleStandard/Article/detail/593667?contextCategoryId=42855&ref=25 A special committee of Genentech's board of directors has agreed to merge with private Swiss drug maker Roche in a deal estimated at $46.8 billion, and the big question being murmured among analysts is whether it will work. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/162009/593667null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Wal-mart-program-will-save-contact-lens-customers-/ArticleStandard/Article/detail/592683?contextCategoryId=42855&ref=25 Wal-Mart Stores along with 1-800 Contacts have a new program that will save customers as much as 12% to 50% on the costs of a yearly supply of contact lenses. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152009/592683null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/HyperBranch-licenses-ocular-bandage-to-BD/ArticleStandard/Article/detail/590868?contextCategoryId=42855&ref=25 HyperBranch Medical Technology Inc. has granted BD Medical-Ophthalmic Systems, a unit of Becton, Dickinson and Co., an exclusive worldwide license to market its liquid ocular bandage (OcuSeal), according to a prepared statement. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/590868null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Bausch-amp-Lomb-launches-initiative-to-raise-presb/ArticleStandard/Article/detail/590901?contextCategoryId=42855&ref=25 Bausch & Lomb has launched a multitiered education initiative to raise consumer awareness of presbyopia and the option of multifocal contact lenses, according to a statement issued by the company. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/590901null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Sirions-supplemental-NDA-for-difluprednate-accepte/ArticleStandard/Article/detail/590866?contextCategoryId=42855&ref=25 The FDA has accepted for review a supplemental new drug application submitted by Sirion Therapeutics Inc., which seeks market approval of difluprednate ophthalmic emulsion 0.05% (Durezol) for the treatment of endogenous anterior uveitis, according to a statement issued by Sirion. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/590866null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/FDA-approves-trypan-blue-015/ArticleStandard/Article/detail/590916?contextCategoryId=42855&ref=25 The FDA has approved trypan blue ophthalmic solution 0.15% (MembraneBlue, Dutch Ophthalmic Research Center International, b.v.) for use as an aid during vitrectomy procedures by staining the epiretinal membranes and, thereby, facilitating the removal of tissue, according to a prepared statement. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/590916null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Eye-care-services-lacking-in-rural-and-low-income-/ArticleStandard/Article/detail/590792?contextCategoryId=42855&ref=25 A lack of access to eye-care services for residents in rural and low-income areas has become a major public health crisis in America, according to analysis from the George Washington University School of Public Health and Health Services. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/590792null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Alcon-launches-Web-site-for-patients-with-nasal-al/ArticleStandard/Article/detail/590899?contextCategoryId=42855&ref=25 Alcon Laboratories Inc. announced in a prepared statement the launch of a new online resource for patients with nasal allergies: its new Web site for olopatadine (Patanase) nasal spray, www.patanese.com. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/590899null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/QLT-completes-phase-Ia-safety-trial-of-synthetic-r/ArticleStandard/Article/detail/590913?contextCategoryId=42855&ref=25 QLT Inc. has released results from its phase Ia trial of QLT091001, a new drug QLT is developing for the potential treatment of Leber's congential amaurosis. 2009-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/590913null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Ophthalmic-community-mourns-the-loss-of-Erin-Jacob/ArticleStandard/Article/detail/588996?contextCategoryId=42855&ref=25 Ophthalmology Times extends its condolences to the ophthalmic community as it mourns the loss of Erin Jacobson, MD, who was killed in a plane crash on Sunday, along with his wife, Amy Jacobson; their children, Jude, Taylor, and Ava; Ms. Jacobson's sister, Vanessa Pullen; her husband, Michael; and their two children. 2009-03-24T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/132009/588996null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/CareCredit-extends-24-month-no-interest-plan/ArticleStandard/Article/detail/588817?contextCategoryId=42855&ref=25 CareCredit is extending the 50% rate reduction on its 24-month, no-interest payment plan through June 30. 2009-03-23T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/132009/588817null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/AAO-launches-free-public-service-Ask-an-Eye-MD/ArticleStandard/Article/detail/588819?contextCategoryId=42855&ref=25 As part of its EyeSmart campaign, the American Academy of Ophthalmology (AAO) has launched "Ask an Eye MD," a new online service through which the public can submit questions about their eyes to a panel of ophthalmologists. 2009-03-23T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/132009/588819null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Bausch-amp-Lomb-Pfizer-to-co-promote-ophthalmic-pr/ArticleStandard/Article/detail/587011?contextCategoryId=42855&ref=25 Bausch & Lomb and Pfizer have entered into a co-promotion agreement that involves both companies? prescription ophthalmic pharmaceuticals in the United States, the companies announced in a joint statement. 2009-03-18T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/587011null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Government-restriction-is-lifted-for-stem-cell-res/ArticleStandard/Article/detail/587008?contextCategoryId=42855&ref=25 President Barack Obama has signed an order to lift restrictions on federal funding for embryonic stem cell research, according to a prepared statement. 2009-03-18T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/587008null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/ThromboGenics-completes-enrollment-for-MIVI-II-DME/ArticleStandard/Article/detail/587014?contextCategoryId=42855&ref=25 ThromboGenics has completed patient enrollment for a phase II trial of microplasmin intravitreal injection for the treatment of diabetic macular edema, according to a statement issued by the company. 2009-03-18T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/587014null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Roche-Genentech-reach-agreement/ArticleStandard/Article/detail/587007?contextCategoryId=42855&ref=25 Roche and Genentech announced that they have signed a merger agreement in which Roche will acquire the outstanding publicly held shares of Genentech for $95 per share, or $46.8 billion, according to statements issued by both companies. 2009-03-18T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/587007null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/iScience-launches-Web-site-for-surgeons/ArticleStandard/Article/detail/587015?contextCategoryId=42855&ref=25 iScience Interventional has launched a new surgeon support Web site, called iForum, that can be viewed at www.iforummd.com, according to a release issued by the company. 2009-03-18T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/587015null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Bausch-amp-Lomb-Santen-enter-into-agreement-for-IO/ArticleStandard/Article/detail/587012?contextCategoryId=42855&ref=25 Bausch & Lomb and Santen Pharmaceutical Co. have entered into a licensing agreement for the development of certain IOL materials, according to statements issued by the companies. Financial terms will not be disclosed. 2009-03-18T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112009/587012null HTML